Castle Biosciences has developed a method to predict the risk of recurrence and metastasis in primary cutaneous squamous cell carcinoma (cSCC) using gene expression levels. This allows for personalized treatment plans, including aggressive therapies, to improve patient outcomes. GlobalData’s report on Castle Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Castle Biosciences Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Castle Biosciences, Personalized medicine biomarkers was a key innovation area identified from patents. Castle Biosciences's grant share as of May 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.

Predicting risk of metastasis in primary cutaneous squamous cell carcinoma

Source: United States Patent and Trademark Office (USPTO). Credit: Castle Biosciences Inc

A recently granted patent (Publication Number: US11976331B2) outlines a method for treating patients with cutaneous squamous cell carcinoma (cSCC) tumors. The method involves obtaining a diagnosis identifying the risk of metastasis in a cSCC tumor sample by measuring the expression levels of 34 specific genes. Based on this analysis, patients are categorized into low or high-risk groups, with aggressive treatments recommended for those deemed to have a high risk of metastasis. These treatments may include radiation therapy, chemoradiation, chemotherapy, surgery, or immunotherapy, aimed at increasing relapse-free survival in high-risk patients.

Furthermore, the patent details the process of determining the expression levels of genes in the gene set, which involves reverse transcribing isolated mRNA and measuring fluorescence levels for each gene. The probability score generated through this analysis helps classify patients into different risk categories, facilitating personalized treatment plans. The method also includes the option of performing a resection of the cSCC tumor in high-risk cases, with the gene set expanded to include control genes for comprehensive analysis. Additionally, the patent highlights the use of radiation therapy as adjuvant or neoadjuvant therapy, or a combination of both, in the treatment of cSCC tumors with moderate to high-risk profiles, as determined by the gene expression analysis.

To know more about GlobalData’s detailed insights on Castle Biosciences, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.